Akseli E. Hemminki

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 224 publications

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.

Journal: Journal for immunotherapy of cancer

Published: July 27, 2026

Alistipes and Eggerthella shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolism.

Alistipes and Eggerthella shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolism.

Journal: Oncoimmunology

Published: April 10, 2026

Recent survival trends in the most fatal cancers in the Nordic countries: gains in some but not in all.

Recent survival trends in the most fatal cancers in the Nordic countries: gains in some but not in all.

Journal: Acta oncologica (Stockholm, Sweden)

Published: April 05, 2026

Does lung adenocarcinoma subtyping offer clinical benefits?-a retrospective population-based cohort study from Sweden.

Does lung adenocarcinoma subtyping offer clinical benefits?-a retrospective population-based cohort study from Sweden.

Journal: Annals of translational medicine

Published: March 10, 2026

Familial Risks in 317 000 Patients With Prostate Cancer in Relation to Metastases and Survival-Guiding Diagnostics.

Familial Risks in 317 000 Patients With Prostate Cancer in Relation to Metastases and Survival-Guiding Diagnostics.

Journal: European urology open science

Published: March 06, 2026

Familial risks in prostate cancer between brothers and half-brothers as clues to germline genetic and environmental causes.

Familial risks in prostate cancer between brothers and half-brothers as clues to germline genetic and environmental causes.

Journal: Familial cancer

Published: January 06, 2026

Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors.

Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: December 01, 2025

Dyslipidaemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumours.

Dyslipidaemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumours.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: July 14, 2025

Dyslipidemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumors.

Dyslipidemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumors.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: July 14, 2025

Second Primary Lung Cancer Associated With Family History of Lung Cancer.

Second Primary Lung Cancer Associated With Family History of Lung Cancer.

Journal: Cancer medicine

Published: July 10, 2025

Oncolytic adenoviruses in platinum-resistant ovarian cancer: a new era in immunotherapy?

Oncolytic adenoviruses in platinum-resistant ovarian cancer: a new era in immunotherapy?

Journal: Expert opinion on biological therapy

Published: May 05, 2025

Mutational landscape of lung adenocarcinoma in Czechia.

Mutational landscape of lung adenocarcinoma in Czechia.

Journal: Cancer treatment and research communications

Published: April 29, 2025

Showing 1-12 of 224

Last Updated: 09/26/2026